
Could Daiichi Sankyo have another ADC winner in cancer?
New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
Newsletters and Deep Dive digital magazine
New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.
Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.
IL-4 inhibitor shows its worth in atopic hand-foot dermatitis unresponsive to corticosteroids.
pharmaphorum’s Deep Dive magazine is back to explore trends, challenges, & innovations in R&D.
Editor's Picks
Newsletters and Deep Dive
digital magazine